Current filters:


Popular Filters

1980 to 2004 of 2442 results

Cancer treatments top breakthrough medicines list, Australian study finds


A cure for cancer is still to be found but more new treatments have been approved for Australians with…

Asia-PacificBiotechnologyHealthcareMarkets & MarketingPharmaceuticalResearch

Bristol-Myers drops hep C pill on patient safety issues


US drug major Bristol-Myers Squibb (NYSE: BMY) has discontinued development of BMS-986094 (formerly known…

Anti-viralsBiotechnologyBMS-986094Bristol-Myers SquibbPharmaceuticalRegulationResearch

Pharming first-half 2012 net loss nearly doubles


Netherlands-based biotech company Pharming (NYSE Euronext: PHARM), which recently revealed that it is…


Gilead abandons development of PAH drug cicletanine


US biotech firm Gilead Sciences (Nasdaq: GILD), the world leader in HIV/AIDS drugs, has discontinued…

BiotechnologycicletanineGilead SciencesRare diseasesResearchRespiratory and Pulmonary

Australia's BTWG opens discussion on cuts to R&D Tax Incentive


The Australian Business Tax Working Group (BTWG) has issued a discussion paper, which includes amongst…


EMA accepts Dynavax' filing for hep B drug Heplisav


US biotech firm Dynavax Technologies (Nasdaq: DVAX) revealed yesterday that the European Medicines Agency…

Anti-viralsBiotechnologyDynavax TechnologiesEuropeHeplisavRegulationVaccines

Study confirms economic viability of orphan drugs positioned for unmet medical needs


Orphan drugs achieve blockbuster status in 2011 and generate over $50 billion in revenue, according to…

BiotechnologyFinancialMarkets & MarketingPharmaceutical

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost


The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…


Pharmacyclics gets second $50 million milestone from Janssen


California, USA-based Pharmacyclics (Nasdaq: PCYC) announced yesterday that the SPARK (MCL2001) clinical…

BiotechnologyFinancialibrutinibJanssenJohnson & JohnsonOncologyPharmaceuticalPharmacyclicsResearch

Dainippon Sumitomo to set up DSP Cancer Institute


Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says it plans to establish a new organization…

BiotechnologyDainippon Sumitomo PharmaManagementOncologyPharmaceuticalResearch

New entrants from Roche and Novartis will drive breast cancer market


Through 2021, the uptake of three new market entrants, Roche (ROG: SIX)/Genentech's Perjeta (pertuzumab)…

AfinitorBiotechnologyMarkets & MarketingNovartisOncologyPerjetaPharmaceuticalRoche

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status


In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

Idenix plunges as FDA puts clinical hold on hepatitis C drug candidate


US biotech firm Idenix Pharmaceuticals (Nasdaq: IDIX) saw its shares tank 29% to $5.91 in morning trading…

Anti-viralsBiotechnologyIdenix PharmaceuticalsIDX184North AmericaPharmaceuticalRegulationResearch

TG Thera in up to $250 million deal with Rhizen


US development stage company TG Therapeutics (GTX:OTC B) has entered into an exclusive global agreement…

BiotechnologyImmunologicalsLicensingOncologyRhizen PharmaceuticalsTG TherapeuticsTGR-1202

UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases


In a final draft guidance issued today, (August 17), the National Institute for Health and Clinical Excellence…


AstraZeneca aligns with Regulus for microRNA therapeutics


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

FDA calls for Biovest to conduct another Ph III trial of BiovaxID in NHL


US biotech firm Biovest International (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals…

BiotechnologyBiovaxIDBiovest InternationalOncologyRegulationResearch

Arrowhead Research Corp improving focus, say Edison analysts


Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

AusBiotech supports discussion paper on Australian national research investment plan


Biotechnology trade group AusBiotech, responding to the Australian federal government's discussion paper…


Low-dose Ampyra fails in multiple sclerosis study, says Acorda


USA-based biotech firm Acorda Therapeutics (Nasdaq: ACOR) has announced top line results from a post-marketing…

Acorda TherapeuticsAmpyraBiotechnologyMetabolicsNeurologicalPharmaceuticalResearch

Cortex and Pier Pharma in all-share merger


USA-based neuroscience company Cortex Pharmaceuticals (OTCBB: CORX) and privately held biotech firm Pier…

BiotechnologyCortex PharmaceuticalsMergers & AcquisitionsNeurologicalPharmaceuticalPier Pharmaceuticals

EMA explains EU incident management plan for human medicines


Earlier this week, the European Medicines Agency published the European Union regulatory network incident…


Pluristem links with Cato Research for PLX-PAD trial in IC indication in Europe


Israeli biotech company Pluristem Therapeutics (TASE: PLTR), a developer of placenta-based cell therapies,…

BiotechnologyCardio-vascularCato ResearchPluristem TherapeuticsPLX-PADResearch

1980 to 2004 of 2442 results

Back to top